Sci. STKE, 17 July 2007
Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells
Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, W/BL 548, Boston, MA 02215, USA.
Abstract: Erythropoietin (Epo) stimulates red blood cell production by docking with its cognate receptor on the erythroid progenitor cell and triggering an array of signaling pathways that inhibit apoptosis and promote cell proliferation and differentiation. In its pharmaceutical forms, epoetin and darbepoetin, Epo is widely used to treat various anemias, including those associated with cancer. The Epo receptor is also expressed by nonhematopoietic cells, including cancer cells, and Epo exhibits a "tissue-protective" effect on nonhematopoietic tissues, possibly mediated through a novel heteroreceptor, blocking apoptosis induced by a variety of insults. The unexpected results of several clinical studies in which Epo was used to treat cancer patients have now raised the question of a potential direct growth-promoting action of Epo on cancer cells.
Citation: A. J. Sytkowski, Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells. Sci. STKE 2007, pe38 (2007).
The editors suggest the following Related Resources on Science sites:
In Science Signaling
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882